181 related articles for article (PubMed ID: 16220064)
1. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.
Mire DE; Silfani TN; Pugsley MK
J Cardiovasc Pharmacol; 2005 Nov; 46(5):585-93. PubMed ID: 16220064
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Sada T; Mizuno M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
4. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
Nussberger J; Koike H
Clin Ther; 2004; 26 Suppl A():A12-20. PubMed ID: 15291375
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan medoxomil: an angiotensin II-receptor blocker.
Brousil JA; Burke JM
Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
[TBL] [Abstract][Full Text] [Related]
6. The role of olmesartan medoxomil in the management of hypertension.
Unger T; McInnes GT; Neutel JM; Böhm M
Drugs; 2004; 64(24):2731-9. PubMed ID: 15563246
[TBL] [Abstract][Full Text] [Related]
7. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF; Franks AM
Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
[TBL] [Abstract][Full Text] [Related]
8. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
9. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
[TBL] [Abstract][Full Text] [Related]
10. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan medoxomil: in children and adolescents with hypertension.
Muir VJ; Keating GM
Drugs; 2010 Dec; 70(18):2439-47. PubMed ID: 21142262
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
[TBL] [Abstract][Full Text] [Related]
14. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Mason RP
Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
Koike H; Sada T; Mizuno M
J Hypertens Suppl; 2001 Jun; 19(1):S3-14. PubMed ID: 11451212
[TBL] [Abstract][Full Text] [Related]
16. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
17. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Yoshida K; Kohzuki M
Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
[TBL] [Abstract][Full Text] [Related]
18. Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.
Smith DH
Am J Hypertens; 2002 Oct; 15(10 Pt 2):108S-114S. PubMed ID: 12383591
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.
Chrysant SG; Dimas B; Shiraz M
J Hum Hypertens; 2007 Sep; 21(9):699-708. PubMed ID: 17554345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
